Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Jennerex Phase II Trial of JX594 Meets Key Clinical Endpoints

FDAnews Drug Daily Bulletin

Sept. 19, 2012 | Vol. 9 No. 184

Jennerex Phase II Trial of JX594 Meets Key Clinical Endpoints

Jennerex has announced positive clinical data from Phase II trial of JX594, a proprietary, engineered oncolytic immunotherapy, in sorafenib-refractory hepatocellular carcinoma (liver cancer, HCC) patients.
Pharmaceutical Business Review

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Full Issue Correction Astellas Scraps EU Marketing Plans for Kidney Cancer Candidate Merck Ends Trials For Once-Promising Parkinson’s Drug

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.